

Standard Commodity Classification No. of Japan	
875200	
Approval No.	16100AMZ04762000
Date of Initial Marketing in Japan	Oct. 1987

Kampo product

JPS Kakkontokasenkyushin'i Extract Granules for Ethical Use

3. COMPOSITION AND PRODUCT DESCRIPTION

3.1 Composition

Product Name	JPS Kakkontokasenkyushin'i Extract Granules for Ethical Use	
Active Ingredients	JP Pueraria Root	4.0 g
	JP Ephedra Herb	4.0 g
	JP Jujube	3.0 g
	JP Cinnamon Bark	2.0 g
	JP Peony Root	2.0 g
	JP Glycyrrhiza	2.0 g
	JP Ginger	1.0 g
	JP Cnidium Rhizome	3.0 g
	JP Magnolia Flower	3.0 g
	7.5 g/day of this product contains 4.6 g of a dried JP Kakkontokasenkyushin'i extract of the above mixed crude drugs.	
Inactive Ingredients	Mg Stearate, Sucrose Esters of Fatty Acids, Lactose Hydrate	

3.2 Product Description

Dosage Form	Granules
Color	Light brown
Smell	Characteristic smell
Taste	Slightly sweet and bitter
ID Code	J-02

4. INDICATIONS

Stuffy nose, empyema, chronic rhinitis

6. DOSAGE AND ADMINISTRATION

The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight, and symptoms.

8. IMPORTANT PRECAUTIONS

8.1 When this product is used, the patient's "SHO" (constitution/symptoms) should be taken into consideration. The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

8.2 Since this product contains Glycyrrhiza, careful attention should be paid to the serum potassium level, blood pressure, etc. [See Sections 10.2, 11.1.1, 11.1.2.]

8.3 When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs.

9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACK GROUNDS

9.1 Patients with Complication or History of Diseases, etc.

9.1.1 Patients in a period of weakness after disease or with extremely weakened constitution

Adverse reactions are likely to occur, and the symptoms may be aggravated.

9.1.2 Patients with an extremely weak gastrointestinal tract
Anorexia, epigastric distress, nausea, vomiting, diarrhea, etc. may occur.

9.1.3 Patients with anorexia, nausea, or vomiting

These symptoms may be aggravated.

9.1.4 Patients with a significant sweating tendency

Excessive sweating, systemic weakness, etc. may occur.

9.1.5 Patients with cardiovascular disorders, including angina pectoris or myocardial infarction, or patients with a history of such disorders

The disease and its symptoms may be aggravated.

9.1.6 Patients with severe hypertension

The disease and its symptoms may be aggravated.

9.1.7 Patients with urination impaired

The disease and its symptoms may be aggravated.

9.1.8 Patients with hyperthyroidism

The disease and its symptoms may be aggravated.

9.2 Patients with Renal Impairment

9.2.1 Patients with severe renal disorder

The disease and its symptoms may be aggravated.

9.5 Pregnant Women

This product should be used in pregnant women or women who may possibly be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment.

9.6 Breast-feeding Women

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered.

9.7 Pediatric Use

No clinical studies have been conducted in children.

9.8 Geriatric Use

Since the physiological functions are generally decreased in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

10. INTERACTIONS

10.2 Precautions for Co-administration (This drug should be administered with caution when co-administered with the following.)

Drugs	Signs, Symptoms, and Treatment	Mechanism and Risk Factors
Ephedra Herb-containing preparations Kakkonto Shoseiryuto Maoto, etc. Ephedrine-containing preparations Ephedrine Hydrochloride dl-Methyl Ephedrine Hydrochloride Fexofenadine Hydrochloride/Pseudoephedrine Hydrochloride, etc. Monoamine Oxidase (MAO) inhibitors Selegiline Hydrochloride Rasagiline Mesilate, etc. Thyroid gland preparations Thyroxine Liothyronine, etc. Catecholamine preparations Adrenaline Isoprenaline, etc. Xanthine preparations Theophylline Diprophylline, etc.	Since insomnia, excessive sweating, tachycardia, palpitation, systemic weakness, mental excitement, etc. are likely to occur, this product should be administered with care by reducing the dosage, etc.	The sympathomimetic effect may be enhanced.
Preparations containing Glycyrrhiza Shakuyakukanzoto Hochuekkito Yokukansan, etc. Preparations containing glycyrrhizic acid and its salts Monoammonium Glycyrrhizinate/Glycine/L-cysteine Monoammonium Glycyrrhizinate/Glycine/DL-methionine combination tablets, etc. [See 8.2, 11.1.1, 11.1.2]	Pseudoaldosteronism is likely to occur. As a result of hypokalaemia, myopathy is likely to occur.	Since glycyrrhizic acid has an accelerating effect on potassium excretion in the renal tubule, an acceleration of decrease in the serum potassium level has been suggested.

11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

11.1 Clinically Significant Adverse Reactions

11.1.1 Pseudoaldosteronism (frequency unknown)

Pseudoaldosteronism such as hypokalaemia, blood pressure increased, retention of sodium/body fluid, edema, and body weight gain may occur. Patients should be carefully monitored (e.g., measurement of serum

potassium levels), and if any abnormalities are observed, administration should be discontinued, and appropriate measures such as administration of potassium preparations should be taken. [See 8.2, 10.2]

11.1.2 Myopathy (frequency unknown)

Myopathy may occur as a result of hypokalaemia. Patients should be carefully monitored, and if any abnormalities such as feelings of weakness, muscle cramp in extremities, or paralysis are observed, administration should be discontinued and appropriate measures such as administration of potassium preparations should be taken. [See 8.2, 10.2]

11.2 Other Adverse Reactions

	Frequency unknown
Hypersensitivity	Rash, Redness, Pruritus, etc.
Autonomic	Insomnia, Excessive sweating, Tachycardia, Palpitations, Systemic weakness, Mental excitement, etc.
Gastrointestinal	Anorexia, Epigastric distress, Nausea, Vomiting, Diarrhea, etc.
Urinary	Urination impaired, etc.

15. OTHER PRECAUTIONS

15.1 Information Based on Clinical Use

Eczema or dermatitis may be aggravated.

20. PRECAUTIONS FOR HANDLING

20.1 To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.

20.2 Avoid moisture, especially after opening, and handle with care.

20.3 Since this product is made from crude drugs, the color of the product may vary.

22. PACKAGING

750 g (2.5 g × 300 packets)

105 g (2.5 g × 42 packets)

24. REFERENCE REQUEST AND CONTACT INFORMATION

JPS Pharmaceutical CO., LTD
4-42-22 Higashiyamata, Tsuzukiku, Yokohama City, Kanagawa Prefecture
224-0023, Japan
TEL : 045-593-2060

26. MARKETING AUTHORIZATION HOLDER, etc.

26.1 Manufactured and Distributed by:

JPS Pharmaceutical CO., LTD
196-1 Hagadai, Hagamachi, Hagagun, Tochigi Prefecture 321-3325, Japan